AIDS antibodies

and ELISA kits, proteins related to AIDS.

Introduction to AIDS

Acquired Immunodeficiency Syndrome (AIDS) remains a critical global health challenge, caused by the Human Immunodeficiency Virus (HIV). Since its identification, extensive research has focused on understanding the virus's mechanisms and developing effective treatments. A key area of advancement lies in the study of antibodies—proteins produced by the immune system to recognize and neutralize pathogens like HIV. Breakthroughs in antibody research have paved the way for innovative therapies and potential vaccines, offering renewed hope in the fight against AIDS. By harnessing the power of these antibodies, scientists aim to prevent viral transmission, inhibit disease progression, and enhance immune responses. Our commitment to AIDS research centers on unlocking the full potential of antibody-based strategies, striving towards a future where AIDS can be effectively managed and ultimately eradicated.

AIDS biomarkers

PA1079

Anti-TNF alpha Antibody Picoband®, Immunomodulatory properties pathway of the hydrogel. (A, B) Flow cytometry analysis of the macrophage surface markers CD11C and CD86. (C) Representative ...

PA1352

Anti-Interleukin-6 IL6 Antibody Picoband®, Experimental workflow. One hundred four rats were randomly divided into five groups: group S (sham, n = 20), group M (middle cerebral artery occlusion...

RP1012

Anti-Interleukin-6 IL6 Antibody Picoband®, Western blot analysis of regulation of protein expression by HIF-1alpha in NCI-H446 cells . According to different treatments, all the cells wer...

Protein Name	Gene Name	Function
CD4	CD4	Surface glycoprotein on T helper cells, primary target of HIV.
Beta-2 microglobulin	B2M	Component of MHC class I; elevated in immune activation.
C-reactive protein (CRP)	CRP	Acute-phase protein serving as a marker of inflammation.
Interleukin-6 (IL-6)	IL6	Pro-inflammatory cytokine indicating immune activation.
Tumor Necrosis Factor-alpha (TNF-α)	TNF	Pro-inflammatory cytokine involved in systemic inflammation.
Soluble CD14 (sCD14)	CD14	Soluble receptor indicating monocyte activation.
D-dimer	F3	Marker of coagulation activation associated with inflammation.
CD38 on CD8 T cells	CD38	Marker of immune activation on cytotoxic T cells.
CCR5	CCR5	Chemokine receptor acting as HIV entry coreceptor.
Programmed cell death protein 1 (PD-1)	PDCD1	Immune checkpoint receptor linked to T cell exhaustion.
Interferon-gamma (IFN-γ)	IFNG	Cytokine vital for immune response against viruses.
sCD163	CD163	Soluble hemoglobin scavenger receptor indicating macrophage activation.

Important Mechanisms

Antiretroviral Therapy

Antiretroviral therapy (ART) is a cornerstone in the management of HIV/AIDS, involving the use of a combination of drugs that target different stages of the HIV life cycle. ART aims to suppress viral replication, thereby reducing the viral load in an individual's blood to undetectable levels. This not only helps in preserving the immune system by preventing the depletion of CD4+ T cells but also significantly reduces the risk of HIV transmission to others. The development of ART has transformed HIV from a fatal disease into a manageable chronic condition, allowing individuals to lead longer, healthier lives. Continuous research in this area focuses on improving drug efficacy, reducing side effects, minimizing the development of drug resistance, and enhancing patient adherence to therapy. Additionally, researchers are exploring long-acting formulations and injectable therapies to simplify treatment regimens and further improve quality of life for those living with HIV.

Vaccine Development

Developing an effective HIV vaccine remains one of the most challenging and critical areas of AIDS research. Unlike other viruses, HIV exhibits high genetic variability and rapid mutation rates, which enable it to evade the immune system and complicate vaccine design. Researchers in this field are focused on understanding the mechanisms of immune recognition and developing strategies to elicit broadly neutralizing antibodies that can target diverse HIV strains. Innovative approaches, such as mRNA vaccine technology, mosaic antigens, and vector-based vaccines, are being explored to stimulate robust and lasting immune responses. The ultimate goal is to create a vaccine that can provide either preventative immunity to uninfected individuals or therapeutic benefits to those already living with HIV by boosting their immune response against the virus. Success in this domain would be a significant breakthrough in the global effort to eradicate HIV/AIDS, as it would offer a sustainable method to prevent new infections and control the spread of the virus worldwide.